Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Retina. 2018 Oct;38(10):1896–1904. doi: 10.1097/IAE.0000000000002302

Table 3.

Cumulative Number of Ranibizumab Injections at Improvement Assessment Visits by Diabetic Retinopathy Improvement Status

Number of injections between baseline and the specified Visit * P-value
**Total no. of injections for each year Improved Not Improved
1-Year Visit N=231 N=70 N=161
 Mean ± SD 8.1 ± 2.6 9.1 ± 2.6 7.6 ± 2.5 < .001
 Median (IQR) 8 (6, 10) 10 (7, 11) 7 (6, 9)
3-Year Visit N=204 N=60 N=144
 Mean ± SD 2.2 ± 2.8 14.9 ± 7.9 12.8 ± 6.3 .05
 Median (IQR) 1 (0, 4) 14 (9, 20) 11 (8, 17)
4-Year Visit N=176 N=49 N=127
 Mean ± SD 1.7 ± 2.6 17.7 ± 9.5 14.4 ± 7.9 .02
 Median (IQR) 0 (0, 3) 15 (10, 23) 13 (8, 19)
5-Year Visit N=163 N=50 N=113
 Mean ± SD 1.9 ± 2.7 21.2 ± 13.1 16.3 ± 8.6 .005
 Median (IQR) 0 (0, 4) 17 (11, 30) 15 (10, 22)

SD= standard deviation; IQR= Interquartile range

*

General linear model used to determine the difference in cumulative number of injections received between eyes with DRS improvement and eyes without DRS improvement

**

Includes all eyes eligible for improvement at each visit; value represents the number of injections in the 12 month period concluding the day before the specified visit.